Research Article
Exhaled Eicosanoids following Bronchial Aspirin Challenge in Asthma Patients with and without Aspirin Hypersensitivity: The Pilot Study
Table 1
Clinical characteristics of the patients.
| | AIA () | ATA () | |
| | Age (y) |
39 () |
39 () | N.S. (0.33) | | Female/Male | 10/11 | 15/8 | N.S. (0.36) | | Duration of asthma (y) |
13 (618) |
7 () | N.S. (0.19) | | Inhaled steroids yes/no | 18/3 | 22/1 | N.S. (0.34) | | Inhaled steroids (μg/d) flutikason |
500 () |
500 () | N.S. (0.93) | | FEV1 baseline (% predicted) placebo/aspirin day |
90.01 () |
91.3 () | N.S. (0.57) | | Total IgE (IU/mL) |
76.3 () |
66.8 () | N.S. (0.78) | | Skin prick test () positive/negative | 10/9 | 15/8 | N.S. (0.53) | | Blood eosinophil count |
*
424 () |
*
232 () | 0.003 |
|
|
Values are expressed as mean ± SD, and median (25% and 75% percentiles).
AIA: aspirin-induced asthma.
ATA: aspirin-tolerant asthma.
|
